Qingdao Haier Biomedical (SHA:688139) terminated its plan to absorb and merge with subsidiary Shanghai RAAS Blood Products (SHE:002252).
The company cited the complexity of the transaction's structure for the termination, according to a Tuesday filing with the Shanghai bourse.
Shares of the biomedical cold chain storage manufacturer were down 11% in recent trade, while shares of Shanghai RAAS fell almost 6%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。